149 Beaumont Avenue
HSRF 208
Burlington, VT 05405
United States
- Postdoctoral Research, Pulmonary antioxidants and environmental lung disease, University of California Davis, Davis, CA
- Ph.D., Department of Pharmacochemistry, Faculty of Chemistry, Vrije Universiteit, Amsterdam, The Netherlands
- B.S./M.S., Subfaculty of Chemistry, Faculty of Mathematics and Physical Sciences, Vrije Universiteit, Amersterdam, The Netherlands
Department of Pathology and Laboratory Medicine
University of Vermont Cancer Center
Cellular, Molecular, & Biomedical Sciences Program Faculty
Areas of expertise
Redox chemistry and biology, Animal models of chronic lung disease, and Epithelial cell biology and extracellular matrix biology.
BIO
Dr. Albert van der Vliet earned his PhD in Pharmacochemistry in 1991 at the Vrije Universiteit in Amsterdam, the Netherlands, and performed postdoctoral training at the University of California at Davis, CA, and at King’s College in London, England. After initial appointments as Assistant and Associate Professor in the Department of Internal Medicine at UC Davis, he relocated to the University of Vermont in 2002, where he is currently a Professor of Pathology and Laboratory Medicine.
My research addresses mechanisms by which environmental or endogenous oxidants impact on pulmonary biology and contribute to chronic lung diseases, including asthma, pulmonary fibrosis and lung cancer. Research is focused primarily on the role of non-phagocytic NADPH oxidases in lung cell biology and pathology, and their involvement in thiol-based redox signaling and oxidative modifications that contribute to extracellular matrix remodeling. Our overarching goal is to develop novel redox-based diagnostic approaches and targeted therapeutic strategies for chronic lung disease.
Our research is primarily based on utilizing biochemistry and proteomics approaches to assess (reversible) redox-based modifications of cellular and extracellular proteins, and their impact on various aspects of cell biology. We use genetic mouse to assess the involvement of enzyme systems that are involved in such redox alterations, particularly NADPH oxidase or heme peroxidases, and their contributions to chronic disease in established animal models. Through collaborative interactions with computational and medical chemists, as well as clinicians, we aim to translate our research findings towards novel drug development and clinical application.
Publications
Bio
Dr. Albert van der Vliet earned his PhD in Pharmacochemistry in 1991 at the Vrije Universiteit in Amsterdam, the Netherlands, and performed postdoctoral training at the University of California at Davis, CA, and at King’s College in London, England. After initial appointments as Assistant and Associate Professor in the Department of Internal Medicine at UC Davis, he relocated to the University of Vermont in 2002, where he is currently a Professor of Pathology and Laboratory Medicine.
My research addresses mechanisms by which environmental or endogenous oxidants impact on pulmonary biology and contribute to chronic lung diseases, including asthma, pulmonary fibrosis and lung cancer. Research is focused primarily on the role of non-phagocytic NADPH oxidases in lung cell biology and pathology, and their involvement in thiol-based redox signaling and oxidative modifications that contribute to extracellular matrix remodeling. Our overarching goal is to develop novel redox-based diagnostic approaches and targeted therapeutic strategies for chronic lung disease.
Our research is primarily based on utilizing biochemistry and proteomics approaches to assess (reversible) redox-based modifications of cellular and extracellular proteins, and their impact on various aspects of cell biology. We use genetic mouse to assess the involvement of enzyme systems that are involved in such redox alterations, particularly NADPH oxidase or heme peroxidases, and their contributions to chronic disease in established animal models. Through collaborative interactions with computational and medical chemists, as well as clinicians, we aim to translate our research findings towards novel drug development and clinical application.